Adagio Says Its COVID-19 Antibody Likely To Retain Activity Against Omicron Variant

Adagio Therapeutics Inc ADGI says that its COVID-19 monoclonal antibody, ADG20, is likely to retain activity against Omicron, as observed in in vitro models with all other variants of concern identified previously. 

• The Company expects the retention due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20.
• ADG20 is an investigational monoclonal antibody (mAb) designed to provide broad and potent neutralizing activity to prevent and treat COVID-19 with a potential duration of protection for up to one year in a single injection.
• Further, none of the mutations present in the spike protein of the Omicron variant have been associated with escape from ADG20 neutralization, the Company said.
• Related Link: Adagio Stock Jumps On Additional Preclinical Data For Its COVID-19 Antibody.
• Adagio is conducting additional in vitro studies to determine the neutralization activity of ADG20 against Omicron.
• Initial data from these studies is anticipated by the end of 2021.
• The Company is also recruiting patients in its Phase 2/3 COVID-19 treatment trial in South Africa to generate data for ADG20 against infections due to the Omicron variant.
• Adagio plans Emergency Use Authorization submissions (EUA) in mid-2022.
• Inventory buildup continues in anticipation of EUA in 2H of 2022, with 4 million doses available for distribution over the next two years.
• Price Action: ADGI shares are up 31.4% at $33.01 during the premarket session on the last check Monday.